NEW YORK (GenomeWeb News) – In advance of a launch of its BRCA1 and BRCA 2 assay, Quest Diagnostics has asked a federal court to declare its test does not infringe patents held by Myriad Genetics.

Quest filed its complaint in US District Court Central District of California on Thursday, asking the court to find that it and the Quest Diagnostics Nichols Institute do not infringe 14 US patents held by Myriad covering BRCA1/2 testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.